Does the media refer more to AUTL or SRPT?

In the previous week, Sarepta Therapeutics had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Sarepta Therapeutics' score of 0.54 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or MESO?

In the previous week, Mesoblast had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 4 mentions for Mesoblast and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Mesoblast's score of 0.31 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NKTR or AUTL?

In the previous week, Nektar Therapeutics had 20 more articles in the media than Autolus Therapeutics. MarketBeat recorded 23 mentions for Nektar Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Nektar Therapeutics' score of 0.13 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUTL or AGIO?

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 3 articles in the media. Autolus Therapeutics' average media sentiment score of 0.55 beat Agios Pharmaceuticals' score of 0.53 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Autolus Therapeutics (AUTL) Competitors

$1.79 -0.04 (-2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.81 +0.02 (+1.12%)

As of 05:05 PM Eastern

Compare

AUTL vs. SRPT, MESO, BHVN, NKTR, and AGIO

Should you buy Autolus Therapeutics stock or one of its competitors? Autolus Therapeutics's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Mesoblast (MESO), Biohaven (BHVN), Nektar Therapeutics (NKTR), and Agios Pharmaceuticals (AGIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Autolus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 446.45%. Sarepta Therapeutics has a consensus price target of $22.71, suggesting a potential upside of 29.82%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Sarepta Therapeutics	7 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sarepta Therapeutics has a net margin of -13.48% compared to Autolus Therapeutics' net margin of -238.66%. Sarepta Therapeutics' return on equity of -1.60% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Autolus Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Autolus Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.46	-$287.53M	-$1.06	N/A
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A

In the previous week, Sarepta Therapeutics had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Sarepta Therapeutics' score of 0.54 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Autolus Therapeutics beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Mesoblast?

Autolus Therapeutics (NASDAQ:AUTL) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Mesoblast had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 4 mentions for Mesoblast and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Mesoblast's score of 0.31 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher revenue and earnings than Autolus Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.46	-$287.53M	-$1.06	N/A
Mesoblast	$120.25M	15.36	-$57.50M	-$0.28	N/A

Autolus Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mesoblast has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Mesoblast's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Mesoblast	N/A	N/A	N/A

Autolus Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 446.45%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 174.26%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Autolus Therapeutics beats Mesoblast on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Autolus Therapeutics had 3 more articles in the media than Biohaven. MarketBeat recorded 3 mentions for Autolus Therapeutics and 0 mentions for Biohaven. Autolus Therapeutics' average media sentiment score of 0.55 beat Biohaven's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biohaven	Neutral
Autolus Therapeutics	Positive

Autolus Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Autolus Therapeutics	$75.39M	6.46	-$287.53M	-$1.06	N/A

Biohaven presently has a consensus price target of $18.69, indicating a potential upside of 43.53%. Autolus Therapeutics has a consensus price target of $10.00, indicating a potential upside of 446.45%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biohaven has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Autolus Therapeutics' return on equity of -178.66% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market.

Summary

Autolus Therapeutics beats Biohaven on 12 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Nektar Therapeutics had 20 more articles in the media than Autolus Therapeutics. MarketBeat recorded 23 mentions for Nektar Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Nektar Therapeutics' score of 0.13 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	2 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	26.10	-$164.08M	-$6.70	N/A
Autolus Therapeutics	$75.39M	6.46	-$287.53M	-$1.06	N/A

Nektar Therapeutics currently has a consensus target price of $138.50, suggesting a potential upside of 228.04%. Autolus Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 446.45%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Autolus Therapeutics has a net margin of -238.66% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the broader market.

Summary

Autolus Therapeutics beats Nektar Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Agios Pharmaceuticals?

Autolus Therapeutics (NASDAQ:AUTL) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Autolus Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.46	-$287.53M	-$1.06	N/A
Agios Pharmaceuticals	$54.03M	34.53	-$412.78M	-$7.01	N/A

Autolus Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 446.45%. Agios Pharmaceuticals has a consensus target price of $41.75, suggesting a potential upside of 33.60%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 3 articles in the media. Autolus Therapeutics' average media sentiment score of 0.55 beat Agios Pharmaceuticals' score of 0.53 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Autolus Therapeutics has a net margin of -238.66% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

Autolus Therapeutics beats Agios Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$476.43M	$3.81B	$7.10B	$13.40B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-1.69	13.23	273.67	26.20
Price / Sales	4.06	1,214.22	595.47	86.09
Price / Cash	N/A	39.04	27.22	34.74
Price / Book	2.67	16.78	11.09	6.35
Net Income	-$287.53M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-3.76%	-3.99%	-2.28%	-0.61%
1 Month Performance	-20.09%	-12.01%	-7.03%	-4.83%
1 Year Performance	14.74%	14.71%	5.66%	1.12%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.5171 of 5 stars	$1.79 -2.2%	$10.00 +458.7%	+13.7%	$476.43M	$117.39M	N/A	752	News Coverage
SRPT Sarepta Therapeutics	2.9911 of 5 stars	$18.80 +0.7%	$24.07 +28.0%	-22.7%	$1.97B	$2.20B	N/A	835	News Coverage Analyst Forecast
MESO Mesoblast	2.2618 of 5 stars	$14.50 -4.1%	$39.00 +169.0%	-22.8%	$1.96B	$120.25M	N/A	108	Gap Down
BHVN Biohaven	2.4477 of 5 stars	$13.28 +2.2%	$18.69 +40.7%	-17.8%	$1.96B	N/A	N/A	274
NKTR Nektar Therapeutics	3.462 of 5 stars	$60.40 +5.9%	$138.50 +129.3%	-30.3%	$1.95B	$55.23M	N/A	63

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. SRPT, MESO, BHVN, NKTR, and AGIO

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Summary

How does Autolus Therapeutics compare to Mesoblast?

Summary

How does Autolus Therapeutics compare to Biohaven?

Summary

How does Autolus Therapeutics compare to Nektar Therapeutics?

Summary

How does Autolus Therapeutics compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. SRPT, MESO, BHVN, NKTR, and AGIO

How does Autolus Therapeutics compare to Sarepta Therapeutics?

Do analysts prefer AUTL or SRPT?

Is AUTL or SRPT more profitable?

Which has more risk and volatility, AUTL or SRPT?

Do institutionals & insiders hold more shares of AUTL or SRPT?

Which has stronger valuation & earnings, AUTL or SRPT?

Does the media refer more to AUTL or SRPT?

Summary

How does Autolus Therapeutics compare to Mesoblast?

Does the media prefer AUTL or MESO?

Which has better earnings & valuation, AUTL or MESO?

Which has more volatility & risk, AUTL or MESO?

Do institutionals and insiders hold more shares of AUTL or MESO?

Is AUTL or MESO more profitable?

Do analysts recommend AUTL or MESO?

Summary

How does Autolus Therapeutics compare to Biohaven?

Does the media refer more to BHVN or AUTL?

Which has preferable valuation and earnings, BHVN or AUTL?

Do analysts rate BHVN or AUTL?

Do institutionals & insiders believe in BHVN or AUTL?

Is BHVN or AUTL more profitable?

Which has more volatility & risk, BHVN or AUTL?

Summary

How does Autolus Therapeutics compare to Nektar Therapeutics?

Does the media favor NKTR or AUTL?

Which has better earnings and valuation, NKTR or AUTL?

Do analysts recommend NKTR or AUTL?

Is NKTR or AUTL more profitable?

Do insiders & institutionals believe in NKTR or AUTL?

Which has more risk & volatility, NKTR or AUTL?

Summary

How does Autolus Therapeutics compare to Agios Pharmaceuticals?

Which has better earnings & valuation, AUTL or AGIO?

Do analysts rate AUTL or AGIO?

Does the media favor AUTL or AGIO?

Which has more risk & volatility, AUTL or AGIO?

Do institutionals and insiders believe in AUTL or AGIO?

Is AUTL or AGIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools